

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A composition for the nasal administration of an antihistamine in a dry powder form suitable for administration of said antihistamine to the nasal region, the dry powder form made by a process comprising the following steps:

providing preformed diketopiperazine microparticles between 10 and 20 microns in diameter;

suspending said diketopiperazine microparticles in an aqueous medium with an antihistamine to form a suspension; and

forming antihistamine-coated diketopiperazine microparticles by removing solvent from said suspension; microparticles comprising the antihistamine and a diketopiperazine

wherein said antihistamine-coated diketopiperazine microparticles are ~~sized such that the particles are preferentially retained in the nasal cavity and have a particle size of~~ between about 10 microns and about 20 microns in diameter, ~~and wherein~~ more than 50% of the microparticles have a particle size greater than about 10 microns, and wherein the particles are maximally retained in the nasal cavity and the composition does not pass into the pulmonary system.

2. (Cancelled)

3. (Previously Presented) The composition of claim 1 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

5. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

6. (Cancelled)

7. (Currently Amended) A drug delivery device for nasal administration comprising

an antihistamine in a dry powder form in a dosage formulation for administration to the nasal region and,

a device for delivering a measured dose of the antihistamine to the nasal mucosa,

wherein the dry powder form comprises microparticles comprising ~~the antihistamine and a diketopiperazine~~ coated with an antihistamine and said antihistamine-coated diketopiperazine microparticles have a particle size of between about 10 microns and about 20 microns in diameter, ~~and wherein~~ more than 50% of the microparticles have a particle size greater than about 10 microns, and wherein the particles are maximally retained in the nasal cavity and the composition does not pass into the pulmonary system.

8. (Original) The device of claim 7 wherein the device is a nasal insufflator.

9. (Cancelled)

10. (Original) The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

11. (Previously Presented) The device of claim 7 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

12. (Previously Presented) The device of claim 7 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

13. (Cancelled)

14. (Currently Amended) A method of administering an antihistamine to the nasal region of a patient in need thereof, comprising:

nasally administering ~~[[a]] the dry powder antihistamine-coated diketopiperazine microparticles of claim 1 suitable for nasal administration, wherein the dry powder form comprises microparticles comprising the antihistamine and a diketopiperazine and said microparticles have a particle size of between about 10 microns and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns; and~~

wherein the composition is maximally retained in the nasal cavity and does not pass into the pulmonary system.

15. (Cancelled)

16. (Original) The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

17. (Previously Presented) The method of claim 14 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

18. (Previously Presented) The method of claim 14 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

19. (Cancelled)

20. (Currently Amended) The composition of claim 1 wherein said antihistamine-coated diketopiperazine microparticles are formed by spray drying.

21. (Currently Amended) The device of claim 7 wherein ~~[[the]]~~ said antihistamine-coated diketopiperazine microparticles are formed by spray drying.

22. (New) The composition of claim 1 wherein said antihistamine-coated diketopiperazine microparticles are formed by lyophilizing.

23. (New) The device of claim 7 wherein said antihistamine-coated diketopiperazine microparticles are formed by lyophilizing.